Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment.
Three unparalleled technologies
Controlled protein fusion, tumour microenvironment drug release,
Scalable industrial process for stochiometric chemical protein fusion
Hypoxic and necrotic tumour microenvironment-specific drug release
Two lead programs
Pancreatic cancer, colorectal cancer, TNBC
First-in-man in 2019
Breast cancer, liposarcoma
First-in-man in 2021
+ Multiple partnered preclinical programs
650 Boulevard Gonthier d'Andernach
Parc d'Innovation, 67400 Illkirch, France
Tel: +33 3 67 10 42 20
Fax: +33 3 67 10 42 06
Feel free to send us an email or use the contact form to leave your message. Our representative will get in touch with you shortly after.